1-855-378-42281-855-378-4228
One of the outpatient rehab alternatives for people in Newtown who are battling with opioid dependence and addiction is called opioid maintenance therapy. Some clinics and doctors are authorized to dispense specific medications to opioid dependent people, many of which are opioids themselves and are addiction. With low enough amounts the client doesn't experience high feelings but also doesn't experience severe cravings and is not experiencing opioid withdrawal. Methadone is the first drug tried for this sole purpose, but there are other options currently to choose from.
Methadone is an opioid and is meant to be taken at an out-patient medical center licensed to administer the med, that is taken daily in liquid or pill form. The cost of the drug is approximately one hundred and fifty dolloars a month. Buprenorphine is also an opioid based drug, and is in pill form often taken every other day. But unlike Methadone which is only be dispensed in structured clinics, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is about three hundred dollars monthly for the generic version of the drug. There is also a version of buprenorphine containing the drug naloxone, which is a med which blocks the effects of opiates. An individual taking this version of the drug, also known as Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It too is taken daily, and costs approximately $450 monthly. Naltrexone is another medication used in opioid maintenance therapy, but unlike the other medications aforementioned it's an opioid blocker and is not an opiate. There is an option to take this medication as a monthly shot, which is called Vivitrol. As an opioid blocker, it prevents someone from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 monthly.
For All Alcohol and Drug Treatment Centers In Newtown, Click Here.
